Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary anti-tumor activity.
Advanced Solid Tumors
DRUG: TGW101
Number of Participants Experiencing Adverse Events (AEs), Up to approximately 10 months|Number of Participants Experiencing Dose Limiting Toxicities (DLTs), Up to Day 21|Number of Participants Experiencing Cycle Delay, Up to approximately 10 months|Number of Participants Experiencing Dose Reduction, Up to approximately 10 months|RDE of TGW101, Up to approximately 10 months
Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of TGW101-ADC Related Analytes, Up to approximately 10 months|Area Under the Concentration-time Curve From Time Zero to the end of the Dosing Interval (AUCtau) of TGW101-ADC Related Analytes, Up to approximately 10 months|Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of TGW101-ADC Related Analytes, Up to approximately 10 months|Maximum Concentration (Cmax) of TGW101-ADC Related Analytes, Up to approximately 10 months|Trough Concentration (Ctrough) of TGW101-ADC Related Analytes, Up to approximately 10 months|Time to Maximum Concentration (Tmax) of TGW101-ADC Related Analytes, Up to approximately 10 months|Apparent Terminal Elimination Half-life (t1/2) of TGW101-ADC Related Analytes, Up to approximately 10 months|Steady-state Volume of Distribution (Vss) of TGW101-ADC Related Analytes, Up to approximately 10 months|Clearance (CL) of TGW101-ADC Related Analytes, Up to approximately 10 months|Accumulation Index of TGW101-ADC Related Analytes, Up to approximately 10 months|Overall Response Rate (ORR), Up to approximately 10 months|Duration of Response (DOR), Up to approximately 10 months|Progression-free Survival (PFS), Up to approximately 10 months|Overall Survival (OS), Up to approximately 10 months|Number of Participants Experiencing Antidrug Antibodies (ADAs) Against TGW101-ADC, Up to approximately 10 months
The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary anti-tumor activity.